RU2692789C2 - Соединение триазина и его применение в медицинских целях - Google Patents

Соединение триазина и его применение в медицинских целях Download PDF

Info

Publication number
RU2692789C2
RU2692789C2 RU2016137263A RU2016137263A RU2692789C2 RU 2692789 C2 RU2692789 C2 RU 2692789C2 RU 2016137263 A RU2016137263 A RU 2016137263A RU 2016137263 A RU2016137263 A RU 2016137263A RU 2692789 C2 RU2692789 C2 RU 2692789C2
Authority
RU
Russia
Prior art keywords
alkyl
compound
mmol
mixture
pharmaceutically acceptable
Prior art date
Application number
RU2016137263A
Other languages
English (en)
Russian (ru)
Other versions
RU2016137263A3 (enExample
RU2016137263A (ru
Inventor
Хиронобу НАГАМОРИ
Икуо МИТАНИ
Масаки ЯМАСИТА
Такахиро ХОТТА
Юйти НАКАГАВА
Масатоси УЕДА
Original Assignee
Джапан Тобакко Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джапан Тобакко Инк. filed Critical Джапан Тобакко Инк.
Publication of RU2016137263A publication Critical patent/RU2016137263A/ru
Publication of RU2016137263A3 publication Critical patent/RU2016137263A3/ru
Application granted granted Critical
Publication of RU2692789C2 publication Critical patent/RU2692789C2/ru

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2016137263A 2014-02-20 2015-02-19 Соединение триазина и его применение в медицинских целях RU2692789C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014031035 2014-02-20
JP2014-031035 2014-02-20
PCT/JP2015/054519 WO2015125842A1 (ja) 2014-02-20 2015-02-19 トリアジン化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
RU2016137263A RU2016137263A (ru) 2018-03-23
RU2016137263A3 RU2016137263A3 (enExample) 2018-10-04
RU2692789C2 true RU2692789C2 (ru) 2019-06-27

Family

ID=53878341

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016137263A RU2692789C2 (ru) 2014-02-20 2015-02-19 Соединение триазина и его применение в медицинских целях

Country Status (32)

Country Link
US (3) US20150266834A1 (enExample)
EP (2) EP3456713A1 (enExample)
JP (4) JP6461637B2 (enExample)
KR (1) KR102360699B1 (enExample)
CN (1) CN106232585B (enExample)
AR (1) AR099498A1 (enExample)
AU (1) AU2015219920B2 (enExample)
BR (1) BR112016018341B1 (enExample)
CA (1) CA2936408C (enExample)
CL (1) CL2016002091A1 (enExample)
CY (1) CY1121261T1 (enExample)
DK (1) DK3109240T3 (enExample)
ES (1) ES2704922T3 (enExample)
HR (1) HRP20182134T1 (enExample)
IL (1) IL247319B (enExample)
LT (1) LT3109240T (enExample)
MX (1) MX369217B (enExample)
MY (1) MY183605A (enExample)
PE (2) PE20211548A1 (enExample)
PH (1) PH12016501651B1 (enExample)
PL (1) PL3109240T3 (enExample)
PT (1) PT3109240T (enExample)
RS (1) RS58235B1 (enExample)
RU (1) RU2692789C2 (enExample)
SA (1) SA516371701B1 (enExample)
SG (1) SG11201606902QA (enExample)
SI (1) SI3109240T1 (enExample)
SM (1) SMT201800684T1 (enExample)
TR (1) TR201821158T4 (enExample)
TW (1) TWI651310B (enExample)
WO (1) WO2015125842A1 (enExample)
ZA (1) ZA201606449B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2772907C2 (ru) * 2015-08-17 2022-05-27 Джапан Тобакко Инк. Соединение гидрокситриазина и его применение в медицинских целях

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN107108467B (zh) * 2014-12-24 2022-08-19 北京生命科学研究所 细胞坏死抑制剂
US11078412B2 (en) * 2015-03-04 2021-08-03 Shimadzu Corporation Polyamine and tyramine analysis method using pyrene containing fluorescence derivatization reagent and excimer fluorescence
EP3339296A4 (en) 2015-08-17 2019-01-23 Japan Tobacco, Inc. HYDROXYTRIAZINE COMPOUND AND USE THEREOF IN MEDICINE
AU2016346557B2 (en) * 2015-10-29 2020-10-29 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
GB201603311D0 (en) * 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
KR102503590B1 (ko) * 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
CA3031563C (en) 2016-08-01 2023-12-05 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
CN110799506B (zh) * 2017-06-26 2024-03-01 默克专利有限公司 用于制备被取代的含氮杂环化合物的方法
CN114502163A (zh) * 2019-07-22 2022-05-13 安吉昂生物医药公司 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙炔基杂环
US11786538B2 (en) * 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
KR102157466B1 (ko) * 2020-05-19 2020-09-17 동아대학교 산학협력단 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물
JP7277676B2 (ja) 2021-02-02 2023-05-19 あすか製薬株式会社 ピリミジン誘導体
EP4553068A1 (en) 2022-07-06 2025-05-14 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivatives

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955060A (en) * 1995-11-23 1999-09-21 Ciba Specialty Chemicals Corporation Bis(resorcinyl)triazines useful as sunscreens in cosmetic preparations
WO2011037610A1 (en) * 2009-09-23 2011-03-31 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
EA201170095A1 (ru) * 2008-06-26 2011-08-30 Мицубиси Танабе Фарма Корпорейшн Производные (4-пиридин-4-ил)-1h-(1,3,5) триазин-2-она в качестве ингибирования gsk3-бета для лечения нейродегенеративных заболеваний
RU2011125917A (ru) * 2008-12-10 2013-01-20 Топхарман Шанхай Ко., Лтд. Производные фенилпиримидона, фармацевтические композиции, способы их получения и применения
WO2013087643A1 (en) * 2011-12-12 2013-06-20 Sanofi 1,3,5 -triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473818A (de) 1964-03-18 1969-06-15 Ciba Geigy Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung
WO1981003020A1 (en) * 1980-04-22 1981-10-29 Commw Scient Ind Res Org Triazine synthesis
SU1313854A1 (ru) 1985-04-17 1987-05-30 Институт Органической Химии Ан Армсср Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
BR9713850A (pt) * 1996-12-05 2000-02-29 Amgen Inc Composto, composição farmacêutica, processos para profilaxia ou tratamento de infecção e de doenças, para diminuir concentrações no plasma de qualquer um ou de ambos tnf-. e o;-1 de qualquer um ou de ambos il-6 e il-8, para profilaxia ou tratamento da doença diabetes e de um distúrbio da dor em um mamìfero, para dimunuir a produção de prostaglandinas em um mamìfero, e, para dimuir a atividade da enzima ciclooxigenase em um mamìfero.
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
ZA9710727B (en) 1996-12-05 1998-06-12 Amgen Inc Substituted pyrimidine compounds and methods of use.
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
TR200102810T2 (tr) 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler
WO2004000820A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
KR101538811B1 (ko) 2007-04-03 2015-07-22 이 아이 듀폰 디 네모아 앤드 캄파니 치환된 벤젠 살진균제
BRPI0913343B1 (pt) 2008-06-04 2018-01-23 Adeka Corporation Método para produção do composto 2,4,6-tri (hidroxifenil)-1,3,5-triazina
JP5388270B2 (ja) 2008-06-04 2014-01-15 株式会社Adeka 2,4,6−トリス(ヒドロキシフェニル)−1,3,5−トリアジン化合物の製造方法
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
AR086254A1 (es) * 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
SI2800743T1 (en) * 2012-01-06 2018-08-31 Agios Pharmaceuticals, Inc. Therapeutically active compounds and methods for their use
AU2013265266A1 (en) 2012-05-23 2015-01-15 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
JP2014031035A (ja) 2012-08-01 2014-02-20 Yamaha Motor Co Ltd 原動機付き鞍乗型車両
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) * 2014-11-13 2016-05-18 东丽纤维研究所(中国)有限公司 一种拒水抗紫外纺织品及其生产方法和用途
EP3339296A4 (en) 2015-08-17 2019-01-23 Japan Tobacco, Inc. HYDROXYTRIAZINE COMPOUND AND USE THEREOF IN MEDICINE
AU2016346557B2 (en) * 2015-10-29 2020-10-29 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955060A (en) * 1995-11-23 1999-09-21 Ciba Specialty Chemicals Corporation Bis(resorcinyl)triazines useful as sunscreens in cosmetic preparations
EA201170095A1 (ru) * 2008-06-26 2011-08-30 Мицубиси Танабе Фарма Корпорейшн Производные (4-пиридин-4-ил)-1h-(1,3,5) триазин-2-она в качестве ингибирования gsk3-бета для лечения нейродегенеративных заболеваний
RU2011125917A (ru) * 2008-12-10 2013-01-20 Топхарман Шанхай Ко., Лтд. Производные фенилпиримидона, фармацевтические композиции, способы их получения и применения
WO2011037610A1 (en) * 2009-09-23 2011-03-31 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
WO2013087643A1 (en) * 2011-12-12 2013-06-20 Sanofi 1,3,5 -triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2772907C2 (ru) * 2015-08-17 2022-05-27 Джапан Тобакко Инк. Соединение гидрокситриазина и его применение в медицинских целях
RU2852458C1 (ru) * 2021-02-02 2025-12-08 Аска Фармасьютикал Ко., Лтд. Производное пиримидина

Also Published As

Publication number Publication date
RU2016137263A3 (enExample) 2018-10-04
CN106232585A (zh) 2016-12-14
BR112016018341A2 (enExample) 2017-08-08
EP3109240B1 (en) 2018-10-24
US20230011968A1 (en) 2023-01-12
AU2015219920A1 (en) 2016-07-14
EP3456713A1 (en) 2019-03-20
JP6461637B2 (ja) 2019-01-30
ES2704922T3 (es) 2019-03-20
WO2015125842A1 (ja) 2015-08-27
US20200087266A1 (en) 2020-03-19
PE20161236A1 (es) 2016-11-23
TWI651310B (zh) 2019-02-21
RS58235B1 (sr) 2019-03-29
JP2021054856A (ja) 2021-04-08
KR102360699B1 (ko) 2022-02-10
PT3109240T (pt) 2019-01-21
CA2936408A1 (en) 2015-08-27
SG11201606902QA (en) 2016-09-29
SMT201800684T1 (it) 2019-01-11
PH12016501651A1 (en) 2017-02-06
SI3109240T1 (sl) 2019-02-28
MY183605A (en) 2021-03-02
PH12016501651B1 (en) 2017-02-06
TR201821158T4 (tr) 2019-01-21
EP3109240A1 (en) 2016-12-28
JP2015172039A (ja) 2015-10-01
CL2016002091A1 (es) 2017-01-20
AR099498A1 (es) 2016-07-27
HRP20182134T1 (hr) 2019-02-08
EP3109240A4 (en) 2017-07-26
CY1121261T1 (el) 2020-05-29
DK3109240T3 (en) 2018-12-17
US20150266834A1 (en) 2015-09-24
MX369217B (es) 2019-10-31
ZA201606449B (en) 2017-11-29
CN106232585B (zh) 2019-04-02
NZ721718A (en) 2021-08-27
MX2016010875A (es) 2016-10-26
US12398111B2 (en) 2025-08-26
KR20160113727A (ko) 2016-09-30
IL247319B (en) 2019-11-28
PL3109240T3 (pl) 2019-03-29
JP2019065036A (ja) 2019-04-25
RU2016137263A (ru) 2018-03-23
AU2015219920B2 (en) 2018-12-20
CA2936408C (en) 2022-09-13
JP2022120173A (ja) 2022-08-17
TW201620881A (zh) 2016-06-16
SA516371701B1 (ar) 2019-01-21
LT3109240T (lt) 2019-01-10
BR112016018341B1 (pt) 2023-02-07
PE20211548A1 (es) 2021-08-16
IL247319A0 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
US12398111B2 (en) Triazine compounds and pharmaceutical use thereof
CN108430994B (zh) 用于调节cftr的化合物、组合物和方法
AU2003211617A1 (en) Ester compound and medicinal use thereof
US12492182B2 (en) Hydroxytriazine compounds and pharmaceutical use thereof
TW201446746A (zh) 經取代的雙環二氫嘧啶酮及其作爲嗜中性白血球彈性酶活性之抑制劑的用途
JP4832897B2 (ja) エステル誘導体及びその医薬用途
HK1228389B (en) Triazine compound and use thereof for medical purposes
HK1228389A1 (en) Triazine compound and use thereof for medical purposes
NZ721718B2 (en) Triazine compound and use thereof for medical purposes
RU2772907C2 (ru) Соединение гидрокситриазина и его применение в медицинских целях
HK40079824A (en) Hydroxytriazine compounds and pharmaceutical use thereof